Article
Author: Thurston, Gavin ; Golubov, Jacquelynn ; Canova, Lauren ; Ramos, Ilyssa ; Dudgeon, Drew ; Haber, Lauric ; Poon, Patrick ; Havel, Lauren ; Ye, Xuan ; Ullman, Erica ; Provoncha, Kathleen ; Yancopoulos, George D. ; Vazzana, Kristin ; Smith, Eric ; Herlihy, Evan ; Lin, John ; Siao, Chia-Jen ; Kim, Julie ; Stokes Oristian, Nicole ; Kirshner, Jessica R. ; Crawford, Alison ; Wang, Bei ; Oswald, Erin ; Poueymirou, William ; Warsaw, Jacqueline J. ; Ajithdoss, Dharani ; Hermann, Aynur ; Wu, Qi ; Sleeman, Matthew A. ; Skokos, Dimitris ; Rafique, Ashique ; Slim, Rabih ; Waite, Janelle C. ; Ahmed, Hassan ; Lazo, Miguel ; Yu, Kevin ; Godin, Stephen ; MacDonald, Douglas ; Ram, Priyanka ; Murphy, Andrew J. ; Potocky, Terra ; Olson, William ; Huang, Tammy ; Chiu, Danica ; Martin, Joel ; Oyejide, Adelekan ; Pawashe, Arpita
CD28 bispecific antibodies are well tolerated and enhance the antitumor efficacy of CD3 bispecifics as a potential off-the-shelf antibody therapy.